每经AI快讯,11月12日,据礼来官微消息,礼来公司公布了eloralintide 2期临床研究的积极结果,eloralintide是一种在研的每周一次给药的选择性胰淀素受体激动剂。该研究在263名不合并2型糖尿病的肥胖或伴有至少一种体重相关合并症的超重成人参与者中,评估了eloralintide的安全性与有效性。在第48周时,eloralintide各剂量组均达到主要终点,平均体重降幅为9.5%...
Source Link每经AI快讯,11月12日,据礼来官微消息,礼来公司公布了eloralintide 2期临床研究的积极结果,eloralintide是一种在研的每周一次给药的选择性胰淀素受体激动剂。该研究在263名不合并2型糖尿病的肥胖或伴有至少一种体重相关合并症的超重成人参与者中,评估了eloralintide的安全性与有效性。在第48周时,eloralintide各剂量组均达到主要终点,平均体重降幅为9.5%...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.